Pramlintide
An FDA-approved synthetic amylin analogue that slows gastric emptying, suppresses glucagon, and enhances meal-related satiety.
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA (as Symlin) as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes. Because amylin is co-secreted with insulin and plays a central role in meal-related satiety, pramlintide has also been investigated for weight management. Randomized trials show it reduces 24-hour caloric intake, meal sizes, and body weight, with effects largely independent of glycemic control. It is a first-generation, short-acting amylin agonist requiring injection before each meal, and its practical role in weight programs has narrowed as long-acting amylin analogues like cagrilintide advance.
Class
Synthetic amylin analogue (peptide)
Half-life
~48 minutes
Routes
Subcutaneous
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Appetite suppression and satiety
Pramlintide activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem, promoting earlier meal termination. RCTs show reduced meal sizes and 24-hour caloric intake in obese adults.
Weight loss
In adults without diabetes, pramlintide produces modest mean weight reductions of roughly 3-5% over 6-month studies, driven by its central satiety mechanism. Reductions are smaller than GLP-1 agonists but arise through a complementary pathway.
Postprandial glucose control
By suppressing post-meal glucagon release and slowing nutrient delivery, pramlintide blunts the after-meal glucose rise, which is the basis for its FDA approval as an adjunct to insulin in diabetes.
Delayed gastric emptying
Pramlintide slows the rate at which the stomach empties, extending the sensation of fullness after eating and moderating the speed of glucose absorption.
Reduced caloric intake
An 8-week dose-response trial documented reductions of 680 to 990 kcal in 24-hour caloric intake versus placebo, reflecting a direct effect on how much food subjects consumed.
Mechanism
How it works
Amylin is a hormone co-secreted with insulin from pancreatic beta-cells that helps regulate glucose appearance in the bloodstream after meals. Pramlintide is a synthetic, more soluble and stable analogue of amylin that reproduces its physiological actions when native amylin is deficient, as occurs in insulin-dependent diabetes.
Pramlintide activates amylin receptors in the hypothalamus and brainstem. It slows gastric emptying so nutrients reach the small intestine more gradually, and it suppresses inappropriate post-meal glucagon secretion, which reduces hepatic glucose output. Together these actions blunt the postprandial glucose spike.
Centrally, pramlintide engages satiety circuits in the area postrema and nucleus tractus solitarius, enhancing the feeling of fullness and reducing food intake. This central satiety signaling is the mechanistic basis for its investigation in obesity and weight management, with weight effects observed independently of improvements in glycemic control.
As a first-generation amylin analogue with a short (~48 minute) half-life, pramlintide must be injected before each major meal to cover post-meal signaling. Longer-acting amylin analogues such as cagrilintide were engineered to extend this action to once-weekly dosing.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Type 1 diabetes (label)
- Dose
- 15 mcg titrated up to 30-60 mcg
- Frequency
- Before each major meal
- Timing
- Immediately prior to meals
- Duration
- Ongoing as adjunct to insulin
- Route
- Subcutaneous
Per FDA labeling; typically initiated at 15 mcg and titrated in 15 mcg increments to a maintenance dose of 30-60 mcg per meal as tolerated. Mealtime insulin is usually reduced to limit hypoglycemia.
Type 2 diabetes (label)
- Dose
- 60 mcg titrated up to 120 mcg
- Frequency
- Before each major meal
- Timing
- Immediately prior to meals
- Duration
- Ongoing as adjunct to insulin
- Route
- Subcutaneous
Per FDA labeling; maintenance dose of 120 mcg per meal. Injected at a site separate from insulin.
Weight management (investigational)
- Dose
- Doses used in obesity trials
- Frequency
- Before meals
- Timing
- Pre-meal
- Duration
- Studied over 6-month periods
- Route
- Subcutaneous
Off-label in non-diabetic patients; trials report mean weight reductions of roughly 3-5% over 6 months. Specific investigational regimens vary by study and are not FDA-labeled for weight loss.
- Pramlintide is injected subcutaneously and, in diabetics, at a site separate from insulin; it must not be mixed in the same syringe with insulin.
- Because of its short half-life, dosing is tied to meals, requiring an injection before each major meal.
- When co-administered with insulin, mealtime insulin doses are typically reduced to lower the risk of hypoglycemia, and doses are titrated gradually.
- Use in non-diabetic weight management is off-label; all dosing decisions should be made under a qualified prescriber's supervision.
Evidence
Research & clinical studies (4)
Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind, dose-response study
In an 8-week dose-response trial (n=88), subcutaneous pramlintide reduced 24-hour caloric intake by 680 to 990 kcal and produced a mean body weight reduction of 2.1% versus a 0.1% gain in placebo-treated obese adults.
PMID 17505051Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and leptin requirements
In a 24-week combination trial (n=177), pramlintide plus metreleptin produced a mean weight reduction of 12.7% versus 8.4% for pramlintide alone and 8.2% for metreleptin alone, suggesting synergistic satiety effects from dual amylin and leptin receptor engagement.
PMID 19521351Pramlintide (LactMed drug and lactation database record)
Pramlintide is unlikely to pass into breastmilk in clinically significant amounts due to its high molecular weight, short half-life, and peptide structure, though limited data suggest monitoring breastfed infants for hypoglycemic symptoms may be warranted.
PMID 30000033In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research
Characterized the in vitro metabolic profiles of weight-loss-inducing amylin receptor agonists to support anti-doping detection methods.
PMID 41702251Combinations
Stacking & blends
Pramlintide + Metreleptin
Enhanced weight loss
Combining an amylin analogue with a leptin analogue engaged both satiety pathways and produced greater 24-week weight reduction (12.7%) than either agent alone in an obesity RCT.
Pramlintide + GLP-1 agonist
Additive appetite and weight reduction
An early-generation dual amylin/incretin approach; combining pramlintide with a GLP-1 agonist has been reported to give additive weight reductions, a concept later optimized in long-acting combinations like CagriSema (cagrilintide + semaglutide).
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Hypoglycemia unawareness
- Gastroparesis (confirmed diagnosis)
Pramlintide carries a moderate risk profile. The most important safety concern is severe hypoglycemia, especially when co-administered with insulin, which is why mealtime insulin is typically reduced and doses titrated gradually. It is not appropriate for individuals with hypoglycemia unawareness or gastroparesis. Always use under professional supervision.
FAQ
Pramlintide — common questions
What is Pramlintide?
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA (as Symlin) as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes. It slows gastric emptying, suppresses post-meal glucagon release, and activates brainstem satiety circuits, which is why it is also studied for weight management.
What is Pramlintide primarily studied for?
Its main studied applications are appetite suppression, postprandial glucose control, weight loss, and delayed gastric emptying.
How much weight can Pramlintide help lose?
In adults without diabetes, pramlintide produces modest mean weight reductions of roughly 3-5% over 6-month studies. This is less than GLP-1 agonists but works through a complementary amylin-based mechanism, and combinations (for example with metreleptin) have shown larger reductions.
How is Pramlintide administered?
Pramlintide is given by subcutaneous injection before major meals. Because its half-life is only about 48 minutes, it must be dosed with each meal rather than once daily or weekly.
What are the side effects of Pramlintide?
The primary concern is hypoglycemia, especially when used alongside insulin; nausea is also common. It is contraindicated in people with hypoglycemia unawareness or gastroparesis. This is educational information only, not medical advice.
How does Pramlintide compare to cagrilintide?
Pramlintide is a first-generation, short-acting amylin analogue requiring an injection before each meal. Cagrilintide is a long-acting amylin analogue designed for once-weekly dosing and is being developed in combination with semaglutide (CagriSema), offering greater convenience and efficacy.
Is Pramlintide FDA approved?
Yes. Pramlintide is FDA-approved as Symlin (NDA 021332, effective March 2005) as an adjunct to insulin therapy in type 1 and type 2 diabetes. Its use for weight loss in non-diabetic patients is off-label.
